Tenon Medical, Inc. Sets Date for First Quarter 2026 Earnings
Tenon Medical (NASDAQ:TNON) will release first quarter 2026 financial results for the period ended March 31, 2026 after market close on Tuesday, May 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tenon Medical (NASDAQ:TNON) will release first quarter 2026 financial results for the period ended March 31, 2026 after market close on Tuesday, May 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time the same day with a Q&A session.
Dial-in numbers, international access, a webcast, and an audio replay available through May 26, 2026 are provided; the telephone replay access code is 13759830.
Details
News Market Reaction – TNON
On May 1, the day this news came out, TNON closed 2.40% above the previous close.
Data tracked by StockTitan Argus for the May 1 session.
Key Figures
- Earnings release date
- May 12, 2026
- Q1 2026 financial results release after market close
- Conference call time
- 4:30 p.m. Eastern Time
- Q1 2026 earnings conference call start time
- US dial-in
- 1-877-407-0792
- Domestic access number for earnings call
- International dial-in
- 1-201-689-8263
- International access number for earnings call
- Replay end date
- May 26, 2026
- End date for audio playback availability
- US replay dial-in
- 1-844-512-2921
- Domestic telephone replay number
- International replay dial-in
- 1-412-317-6671
- International telephone replay number
- Replay access code
- 13759830
- Access code for telephone replay
Previous Earnings date Reports
-
Announced Q4/FY2025 earnings date and reaffirmed revenue ranges with call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS GATOS, CA / ACCESS Newswire / May 1, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the first quarter ended March 31, 2026 after market close on Tuesday, May 12, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.
Date: | Tuesday, May 12, 2026 |
Time: | 4:30 p.m. Eastern time |
Dial-in: | 1-877-407-0792 |
International Dial-in: | 1-201-689-8263 |
Webcast: |
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
An audio playback of the call will be available through May 26, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13759830.
About Tenon Medical, Inc.
Tenon Medical, Inc. is a medical device company founded in 2012 and committed to developing novel technologies for patients suffering from debilitating SI joint pain and dysfunction. The Company markets the Catamaran® and SImmetry+® SI Joint Fusion Systems, which offer a novel, less invasive approach to treating SI joint disease. Together, these platforms uniquely position Tenon with multiple surgical approaches, lateral and inferior-posterior, both designed to be minimally invasive, enable authentic arthrodesis, and supported by robust clinical evidence, including the published prospective Mainsail™ and EVoluSIon™ SI joint fusion studies. These differentiated technologies enable physicians to customize treatment plans through an innovative portfolio spanning SI joint fusion, spinal fusion, and deformity adjuncts, each solution engineered to deliver fusion outcomes more reliably. This multi-platform, multiapproach strategy strengthens Tenon's competitive advantage in the expanding SI joint fusion market and underscores the Company's commitment to delivering proven, durable outcomes for physicians and patients. Tenon is focused on three commercial opportunities in the SI joint market: 1) primary SI joint procedures, 2) revision of failed SI joint implants, and 3) augmenting spinal fusion. For more information, please visit www.tenonmed.com.
The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.
Investor Contact
Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us
SOURCE: Tenon Medical, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.